Tag: auristatins
The Rise of HER2-targeting ADCs and the Journey from Breakthrough Therapy...
Antibody-drug conjugates (ADCs) as precision targeted cancer therapies have started to deliver on their early promise as an innovative novel drug modality as demonstrated...
Novel Payloads for Antibody-drug Conjugates
The development of antibody-drug conjugates or ADCs, has resulted in the need of developing novel compounds that can be used as payloads.
Enediynes, represented by...
AACR 2018: Highlighting Novel Antibody-Drug Conjugate Technologies and Immuno-Oncology
This year, the American Association for Cancer Research (AACR) will host their annual meeting April 14 - 18, 2018 in the McCormick Place North/South...
Pfizer and Seattle Genetics Agree on Antibody-Drug Conjugate Collaboration
Pfizer and Seattle Genetics, a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer ,...
